diagnost tool
price close busi februari
fast-grow compani anim health
diagnost seek take modest us market
share gain expand intern time
move valu chain reiter buy
trim estim pt ahead call next week
last week privileg host investor meet heska ceo
kevin wilson director ir jon aagaard believ meet reinforc
long-term thesi stock global expans new product scarciti valu
diagnost support buy thesi near term investor await guid
earn call next tuesday view near-term risk event stock
would apt put new money work report set bar
move valu chain believ investor know appreci
livestock/poultry/dairi lpd busi valu sinc growth
busi declin plan manufactur new immunodiagnost
rotor chemistri consum de moin ia leverag usda-
regul manufactur facil longer term think get credit
manufactur product accret today use oem
revenu
guid think key call guid expect
growth consum instrument growth expect downsid lpd
possibl instrument vs street recal lpd lower-gm unit faster-
grow consum thu think lpd shortfal thesi changer
near-term risk also see higher spend year histori
larg clinic win newer launch box run patient sampl
time similar catalyst lower all-in cost ownership mark key reason
larg corpor win petvet pathway vet allianc etho announc
see opportun ahead obviou posit
catalyst call tuesday feb guid launch rotor
chemistri ou launch immunodx analyz
news ou launch new tuck-in deal launch urine-fec uf
analyz
zts/abax impact note seen chang field result
zts-abax merger suggest earli think abax longer
donor point share year point share donor split
zts/abax team bundl rotor therapeut also opin
acquir abaxi acceler abil test treat larg
ingelheim rev acquir merial anoth global anim health
compani like elanco merck bayer hillhous china
expans acquir busi beachhead
franc revenu ad revenue model compani still prefer
partner larg establish firm suspect potenti deal
indic presenc franc see quit
opportun ou bolt tuck-in tune rev thu think
like remain acquisit pay deal cash
remain question us option financ
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
lower estim pt bake conserv outlook
non-cor revenu unit lpd busi portion instrument
busi clear view lower estim turn bearish
rather realist compani non-cor lower-margin segment
lower pt use previous use
multipl revenu estim previous model
revenu discount back year unchang discount rate
unchang share outstand unchang
lower revenu estim prior
consensu
addit lower out-year ep estim reflect combin lower
revenu higher-than-we-previously-expect spend compani look
manufactur newer product de moin iowa facil lower
ep estim prior
street took slightli conserv outlook
gm expans expect flattish gm lift lower-margin non-
core busi shrink higher-margin consum continu grow double-digit
may realiz gm benefit manufactur product
realist expect like beyond lower revenu
estim beyond includ revenu associ new
franc acquisit model partial quarter contribut
intern expans earli januari agre acquir
unnam compani franc manufactur endoscopi equip vet
deal expect close within next sever week add
revenu model beachhead franc note paid rev
compani indic busi franc employe provid
offic pari custom possess
point-of-car diagnost analyz expect franc compani acquisit
neutral ep year accret thereaft acquisit compani
chang strategi intern expans still prefer work
larg establish partner suspect though observ
busi recent spun think
patienc may warrant announc ou deal
manag indic materi presenc franc
thu move franc would redund sign larg ou distribut deal
see quit opportun ou bolt tuck-in tune
revenu thu think like remain acquisit even spoke
opportun acquir revenu one sever possibl
deal ou compani pay futur acquisit remain question us
option financ busi build australia
month expect first revenu australia come around feb
also target new partner middl east ukrain eastern europ
select asian countri doesnt coverag
indic intern design urine-fec analyz expect
launch result may invest increment
 near term get product market launch urine-fec
analyz would first ever autom urin fecal instrument instrument
think would particularli valuabl veterinarian global
indic rep field though focus
imag thu rep focus core market
indic may provid addit disclosur upcom call
help analyst investor pars growth rate certain bucket exampl
compani infus pump busi declin report
compani instrument revenu bucket expect may provid greater
visibility/transpar compon possibl growth rate within
ask strength end-market vet clinic respons
recent commentari data base pet clinic shown declin pet
buy unchang target price februari
diagnost tool
offic visit indic continu see good growth end market though
suspicion may track end user data close
 buy said obvious track consum
growth level growth easili double-digit steadi
indic still-solid growth recur revenu anim health diagnost
despit slowdown offic visit hypothesi declin foot traffic
anim health clinic may function pet owner tri busi via
ask investor worri indic matter
relat quarter-to-quart lumpi compani non-cor busi eventu
get smaller recur revenu grow larger percentag revenu
ultim reduc quarter-to-quart lumpi
estim market share anim health diagnost unit
state follow abaxi noth
estim terribl differ trail survey data
suggest abaxi none/greenfield
caution data come survey respons time
tini fraction clinic us survey data also repres
averag last three year like exclud abaxi recent share loss
recent share gain link recent anim health survey
found
bull thesi intact acknowledg trim estim
pt primarili relat lower estim non-cor busi
buy-thesi remain intact link takeaway compani
analyst day primari chang current think think
analyst day function lower revenu estim compani non-cor
busi segment slightli lower margin assumpt push-out compani
urine-fec instrument plan launch combin instrument
earli januari investor confer provid time updat
new product launch optimist hska variou new product launch
nice addit hska top-lin growth rate time howev one concern
investor may need wait see much impact
indic expect move forward combin urin fecal analyz
togeth onto one platform perhap logic continu manag think
commun analyst call part result combin two
expect launch uf mark delay rel time announc
analyst day compani origin commun urin
fecal view delay disappoint risk thesi top
pick investor need push growth box view risk
thesi mark yet anoth bridg year next year regardless
think new product set nice futur growth inflect think
mark solid growth compani execut intern
expans benefit traction new product coupl possibl market
share gain unit state
element uf look provid automat imag annual urin sediment
exam manual point-of-car fecal flotat exam complet year
expect launch serv industri first dual urine-fec analyz
size combin opportun urin fecal
indic valid abil combin urin fecal onto one
analyz indic product launch near term
excit uf
hska near-term product launch includ element rc rotor-bas chemistri
analyz element multiplex immunodiagnost platform expect
launch note time analyst day
hska element rc analyz design primarili ou custom first-tim
user chemistri analyz element rc abil run test
rotor vs abaxi tests/rotor view competit advantag
buy unchang target price februari
diagnost tool
compar legaci non-multiplex immunodiagnost platform element
lower cost faster higher sensit allow multiplex
intend launch element total cortisol assay
compris revenu flow legaci immunodiagnost box
intend launch test heartworm lyme anaplasma ehrlichia
like opinion view test opportun
roughli custom long-term subscript model six-year
term agreement tend monthli minimum
annual price escal indic subscript end
indic corpor vet hospit us vs
nascent chines market point rise interest veterinari invest
china evidenc hillhous capit group one china largest ventur fund
acquisit chines vet hospit
buy unchang target price februari
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
diagnost tool
buy unchang target price februari
diagnost tool
